share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  06/25 17:21

Moomoo AI 已提取核心訊息

On June 24, 2024, eFFECTOR Therapeutics, Inc. received a notification from Nasdaq's Listing Qualifications Staff indicating that the company is considered a 'public shell' following its announcement to terminate employees and wind down operations. This determination was made because eFFECTOR Therapeutics no longer meets Nasdaq's listing requirements, including those related to board independence and committee compositions. Additionally, the company has failed to maintain the minimum market value of listed securities of $35 million, a non-compliance issue previously disclosed on May 17, 2024. Consequently, Nasdaq plans to suspend trading of eFFECTOR Therapeutics' common stock on July 3, 2024, and will proceed with delisting the company's securities. eFFECTOR Therapeutics has decided not to appeal this decision and intends to file a Form 15 to suspend its reporting obligations under the Securities Exchange Act of 1934.
On June 24, 2024, eFFECTOR Therapeutics, Inc. received a notification from Nasdaq's Listing Qualifications Staff indicating that the company is considered a 'public shell' following its announcement to terminate employees and wind down operations. This determination was made because eFFECTOR Therapeutics no longer meets Nasdaq's listing requirements, including those related to board independence and committee compositions. Additionally, the company has failed to maintain the minimum market value of listed securities of $35 million, a non-compliance issue previously disclosed on May 17, 2024. Consequently, Nasdaq plans to suspend trading of eFFECTOR Therapeutics' common stock on July 3, 2024, and will proceed with delisting the company's securities. eFFECTOR Therapeutics has decided not to appeal this decision and intends to file a Form 15 to suspend its reporting obligations under the Securities Exchange Act of 1934.
2024年6月24日,eFFECTOR Therapeutics公司收到了納斯達克的上市資格工作人員的通知,表明該公司被視爲“公共殼牌”,在宣佈解僱員工和停止運營後。這一決定的原因是eFFECTOR Therapeutics不再符合納斯達克的上市要求,包括與董事會獨立性和委員會組成相關的要求。此外,該公司未能保持上市證券的最低市值爲3500萬美元,這是一個於2024年5月17日已經披露的不合規問題。因此,納斯達克計劃於2024年7月3日暫停eFFECTOR Therapeutics普通股的交易,並將繼續退市該公司的證券。eFFECTOR Therapeutics已決定不對此決定提出上訴,並打算提交15號表格,以暫停其根據《1934年證券交易所法》的報告義務。
2024年6月24日,eFFECTOR Therapeutics公司收到了納斯達克的上市資格工作人員的通知,表明該公司被視爲“公共殼牌”,在宣佈解僱員工和停止運營後。這一決定的原因是eFFECTOR Therapeutics不再符合納斯達克的上市要求,包括與董事會獨立性和委員會組成相關的要求。此外,該公司未能保持上市證券的最低市值爲3500萬美元,這是一個於2024年5月17日已經披露的不合規問題。因此,納斯達克計劃於2024年7月3日暫停eFFECTOR Therapeutics普通股的交易,並將繼續退市該公司的證券。eFFECTOR Therapeutics已決定不對此決定提出上訴,並打算提交15號表格,以暫停其根據《1934年證券交易所法》的報告義務。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息